Brett Delahunt

Summary

Country: New Zealand

Publications

  1. ncbi Fuhrman grading is not appropriate for chromophobe renal cell carcinoma
    Brett Delahunt
    Department of Pathology and Molecular Medicine, Wellington School of Medicine and Health Sciences, New Zealand
    Am J Surg Pathol 31:957-60. 2007
  2. ncbi The evolution of collagen expression in sarcomatoid renal cell carcinoma
    Brett Delahunt
    Department of Pathology and Molecular Medicine, Wellington School of Medicine and Health Sciences, PO Box 7343, Wellington South, New Zealand
    Hum Pathol 38:1372-7. 2007
  3. ncbi Thyroid gland clonality revisited: the embryonal patch size of the normal human thyroid gland is very large, suggesting X-chromosome inactivation tumor clonality studies of thyroid tumors have to be interpreted with caution
    Lidija Jovanovic
    Department of Pathology and Molecular Medicine, Wellington School of Medicine and Health Sciences, Wellington 6002, New Zealand
    J Clin Endocrinol Metab 88:3284-91. 2003
  4. doi Distinct genetic changes characterise multifocality and diverse histological subtypes in papillary thyroid carcinoma
    Lidija Jovanovic
    Department of Pathology and Molecular Medicine, Wellington School of Medicine and Health Sciences, University of Otago, Wellington, New Zealand
    Pathology 42:524-33. 2010
  5. doi Grading of clear cell renal cell carcinoma should be based on nucleolar prominence
    Brett Delahunt
    Department of Pathology and Molecular Medicine, Wellington School of Medicine and Health Sciences, University of Otago Wellington, Wellington, New Zealand
    Am J Surg Pathol 35:1134-9. 2011
  6. ncbi Demographic and clinical factors as determinants of serum levels of prostate specific antigen and its derivatives
    Marion A Gray
    Department of Public Health, Wellington School of Medicine and Health Sciences, University of Otago, Wellington, New Zealand
    Anticancer Res 24:2069-72. 2004
  7. ncbi Outcome prediction for renal cell carcinoma: evaluation of prognostic factors for tumours divided according to histological subtype
    Brett Delahunt
    Department of Pathology and Molecular Medicine, Wellington School of Medicine and Health Sciences, Wellington South, New Zealand
    Pathology 39:459-65. 2007
  8. ncbi Nucleolar grade but not Fuhrman grade is applicable to papillary renal cell carcinoma
    Dianne Sika-Paotonu
    Department of Pathology and Molecular Medicine, Wellington School of Medicine and Health Sciences, Wellington, New Zealand
    Am J Surg Pathol 30:1091-6. 2006
  9. doi Clinical significance of cancer in radical prostatectomy specimens: analysis from a contemporary series of 2900 men
    Hemamali Samaratunga
    1Aquesta Pathology, Brisbane 2University of Queensland, Brisbane, Queensland, Australia 3Department of Pathology and Molecular Medicine, Wellington School of Medicine and Health Sciences, University of Otago, Wellington 4Royal Brisbane Hospital, Brisbane, Queensland, Australia 5Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada 6Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden 7Department of Surgery, Wellington School of Medicine and Health Sciences, University of Otago, Wellington, New Zealand
    Pathology 46:11-4. 2014
  10. ncbi Prostate cancer--are ethnic minorities disadvantaged?
    David S Lamb
    Department of Pathology and Molecular Medicine, University of Otago Wellington, P O Box 7343, Wellington 6242, New Zealand
    Anticancer Res 28:3891-5. 2008

Collaborators

Detail Information

Publications32

  1. ncbi Fuhrman grading is not appropriate for chromophobe renal cell carcinoma
    Brett Delahunt
    Department of Pathology and Molecular Medicine, Wellington School of Medicine and Health Sciences, New Zealand
    Am J Surg Pathol 31:957-60. 2007
    ..It is concluded that neither Fuhrman grading, nor any of the components of the Fuhrman grading system, is useful as prognostic indicators for this tumor type...
  2. ncbi The evolution of collagen expression in sarcomatoid renal cell carcinoma
    Brett Delahunt
    Department of Pathology and Molecular Medicine, Wellington School of Medicine and Health Sciences, PO Box 7343, Wellington South, New Zealand
    Hum Pathol 38:1372-7. 2007
    ....
  3. ncbi Thyroid gland clonality revisited: the embryonal patch size of the normal human thyroid gland is very large, suggesting X-chromosome inactivation tumor clonality studies of thyroid tumors have to be interpreted with caution
    Lidija Jovanovic
    Department of Pathology and Molecular Medicine, Wellington School of Medicine and Health Sciences, Wellington 6002, New Zealand
    J Clin Endocrinol Metab 88:3284-91. 2003
    ..Therefore, monoclonality in neoplastic and hyperplastic lesions may just be a reflection of normal thyroid epithelium clonal composition...
  4. doi Distinct genetic changes characterise multifocality and diverse histological subtypes in papillary thyroid carcinoma
    Lidija Jovanovic
    Department of Pathology and Molecular Medicine, Wellington School of Medicine and Health Sciences, University of Otago, Wellington, New Zealand
    Pathology 42:524-33. 2010
    ..This study was undertaken to investigate the genetic factors underlying the development of multifocality and phenotypic diversity in multifocal papillary thyroid carcinoma (mPTC)...
  5. doi Grading of clear cell renal cell carcinoma should be based on nucleolar prominence
    Brett Delahunt
    Department of Pathology and Molecular Medicine, Wellington School of Medicine and Health Sciences, University of Otago Wellington, Wellington, New Zealand
    Am J Surg Pathol 35:1134-9. 2011
    ..These findings indicate that worst nucleolar grading alone is a valid grading parameter for clear cell renal cell carcinoma...
  6. ncbi Demographic and clinical factors as determinants of serum levels of prostate specific antigen and its derivatives
    Marion A Gray
    Department of Public Health, Wellington School of Medicine and Health Sciences, University of Otago, Wellington, New Zealand
    Anticancer Res 24:2069-72. 2004
    ....
  7. ncbi Outcome prediction for renal cell carcinoma: evaluation of prognostic factors for tumours divided according to histological subtype
    Brett Delahunt
    Department of Pathology and Molecular Medicine, Wellington School of Medicine and Health Sciences, Wellington South, New Zealand
    Pathology 39:459-65. 2007
    ..Although some of these markers have been shown to be significantly associated with survival, these findings remain to be confirmed in large scale follow-up studies...
  8. ncbi Nucleolar grade but not Fuhrman grade is applicable to papillary renal cell carcinoma
    Dianne Sika-Paotonu
    Department of Pathology and Molecular Medicine, Wellington School of Medicine and Health Sciences, Wellington, New Zealand
    Am J Surg Pathol 30:1091-6. 2006
    ....
  9. doi Clinical significance of cancer in radical prostatectomy specimens: analysis from a contemporary series of 2900 men
    Hemamali Samaratunga
    1Aquesta Pathology, Brisbane 2University of Queensland, Brisbane, Queensland, Australia 3Department of Pathology and Molecular Medicine, Wellington School of Medicine and Health Sciences, University of Otago, Wellington 4Royal Brisbane Hospital, Brisbane, Queensland, Australia 5Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada 6Department of Oncology and Pathology, Karolinska Institutet, Stockholm, Sweden 7Department of Surgery, Wellington School of Medicine and Health Sciences, University of Otago, Wellington, New Zealand
    Pathology 46:11-4. 2014
    ..These results suggest that, contrary to estimates from international trials, ad hoc PSA testing is associated with low levels of over-treating...
  10. ncbi Prostate cancer--are ethnic minorities disadvantaged?
    David S Lamb
    Department of Pathology and Molecular Medicine, University of Otago Wellington, P O Box 7343, Wellington 6242, New Zealand
    Anticancer Res 28:3891-5. 2008
    ....
  11. doi Gleason scoring: a comparison of classical and modified (international society of urological pathology) criteria using nadir PSA as a clinical end point
    Brett Delahunt
    Department of Pathology and Molecular Medicine, Wellington School of Medicine and Heath Sciences, University of Otago, Wellington, New Zealand
    Pathology 42:339-43. 2010
    ..To compare the distribution and predictive performance of Gleason grade and scores derived using classical and modified (International Society of Urological Pathology) criteria...
  12. doi The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters
    Brett Delahunt
    Department of Pathology and Molecular Medicine, Wellington School of Medicine and Health Sciences, University of Otago, Wellington, New Zealand Department of Pathology, Mayo Clinic, Rochester, MN Department of Pathology and Immunology, Washington University School of Medicine, St Louis, MO Department of Anatomic Pathology, Cancer Biology and Glickman Urological Institute, Cleveland, OH Department of Pathology, Indiana University School of Medicine, Indianapolis, IN Dipartimento di Patologia e Diagnostica, Universita di Verona, Verona The Institute of Pathological Anatomy and Histopathology, University of Ancona School of Medicine, Ancona, Italy Department of Oncology and Pathology, Karolinska University Hospital, Solna, Stockholm, Sweden Department of Pathology, Fundacion Puigvert University Antonomous, Barcelona, Spain University of Zurich, Switzerland Department of Laboratory Medicine, Credit Valley Hospital, Mississauga Department of Pathology and Molecular Medicine, McMaster University, Toronto, ON, Canada
    Am J Surg Pathol 37:1490-504. 2013
    ..It was agreed upon that chromophobe RCC should not be graded. There was consensus that microvascular invasion should not be included as a staging criterion for RCC. ..
  13. ncbi Optimising restriction enzyme cleavage of DNA derived from archival histopathological samples: an improved HUMARA assay
    Lidija Jovanovic
    Department of Pathology and Molecular Medicine, Wellington School of Medicine and Health Sciences, Wellington, New Zealand
    Pathology 35:70-4. 2003
    ....
  14. ncbi High resolution loss of heterozygosity mapping of 17p13 in thyroid cancer: Hurthle cell carcinomas exhibit a small 411-kilobase common region of allelic imbalance, probably containing a novel tumor suppressor gene
    Kathryn Farrand
    Department of Pathology and Molecular Medicine, Wellington School of Medicine, New Zealand
    J Clin Endocrinol Metab 87:4715-21. 2002
    ..These data suggest that a TSG, involved in HCC pathogenesis, is contained within the D17S1308-D17S695 interval. There are several potential candidate TSGs in this region that are worthy of further study...
  15. doi A novel grading system for clear cell renal cell carcinoma incorporating tumor necrosis
    Brett Delahunt
    Department of Pathology and Molecular Medicine, Wellington School of Medicine and Health Sciences, University of Otago, Wellington, New Zealand
    Am J Surg Pathol 37:311-22. 2013
    ..We conclude that grading for clear cell RCC should be based on nucleolar prominence and necrosis, that ISUP grading should be used for papillary RCC, and that chromophobe RCC should not be graded...
  16. doi Gleason grading: past, present and future
    Brett Delahunt
    Department of Pathology and Molecular Medicine, Wellington School of Medicine and Health Sciences, University of Otago, Wellington, New Zealand
    Histopathology 60:75-86. 2012
    ....
  17. doi Advances and controversies in grading and staging of renal cell carcinoma
    Brett Delahunt
    Department of Pathology and Molecular Medicine, Wellington School of Medicine and Health Sciences, University of Otago Wellington, PO Box 7343, Wellington South, New Zealand
    Mod Pathol 22:S24-36. 2009
    ..Although the current TNM classification does provide useful prognostic information it would appear that further modifications are justified to enhance the predictive value of staging for RCC...
  18. ncbi History of the development of the classification of renal cell neoplasia
    Brett Delahunt
    Department of Pathology and Molecular Medicine, Wellington School of Medicine and Health Sciences, 23A Mein Street, Wellington South, New Zealand
    Clin Lab Med 25:231-46, v. 2005
    ..This article reviews the history of the development of the classification of renal cell neoplasia...
  19. ncbi Intragenic PTEN/MMAC1 loss of heterozygosity in conventional (clear-cell) renal cell carcinoma is associated with poor patient prognosis
    Marija Velickovic
    Department of Pathology and Molecular Medicine, Wellington School of Medicine and Health Sciences, Newtown, Wellington, New Zealand
    Mod Pathol 15:479-85. 2002
    ..Biallelic inactivation may preferentially occur by nonmutational mechanisms, or, alternatively, haploinsufficiency of PTEN/MMAC1 may be sufficient to affect tumor progression in cRCC...
  20. ncbi Prostate cancer: the new evidence base for diagnosis and treatment
    David S Lamb
    Department of Pathology and Molecular Medicine, Wellington School of Medicine and Health Sciences, and Department of Radiation Oncology, Wellington Hospital, New Zealand
    Pathology 39:537-44. 2007
    ..These improvements mean that now most men aged 50-70 years diagnosed with PC will have clinically significant cancers that require treatment...
  21. doi Therapy-associated effects in the prostate gland
    John R Srigley
    Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada
    Histopathology 60:153-65. 2012
    ..As new therapies are developed for prostate cancer, it is important to document their effects on benign and malignant prostate tissue and to understand possible implications for traditional prognostic factors, especially Gleason grade...
  22. doi Recently described and unusual variants of urothelial carcinoma of the urinary bladder
    Hemamali Samaratunga
    Aquesta Pathology, Queensland, Australia
    Pathology 44:407-18. 2012
    ....
  23. ncbi Assessment of ethnic variation in serum levels of total, complexed and free prostate specific antigen. Comparison of Maori, Pacific Island and New Zealand European populations
    Marion A Gray
    Department of Public Health, Wellington School of Medicine and Health Sciences, PO Box 7343, University of Otago, Wellington South, New Zealand
    Pathology 35:480-3. 2003
    ..To determine whether age-adjusted levels of serum total (tPSA) and complexed (cPSA) prostate specific antigen and the ratio of free to tPSA (%fPSA) differ by ethnic group independent of symptomatic disease...
  24. ncbi Renal cell neoplasia
    Brett Delahunt
    Department of Pathology and Molecular Medicine, Wellington School of Medicine, New Zealand
    Pathology 34:13-20. 2002
  25. ncbi Chromosomal gains in the sarcomatoid transformation of chromophobe renal cell carcinoma
    Matteo Brunelli
    Anatomia Patologica, Dipartimento di Patologia, Universita di Verona, Verona, Italy
    Mod Pathol 20:303-9. 2007
    ....
  26. ncbi Expanding the histologic spectrum of mucinous tubular and spindle cell carcinoma of the kidney
    Samson W Fine
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Am J Surg Pathol 30:1554-60. 2006
    ..Pathologists must be aware of the spectrum of histologic findings within MTSCs to ensure their accurate diagnosis...
  27. ncbi Renal mucinous tubular and spindle carcinoma lacks the gains of chromosomes 7 and 17 and losses of chromosome Y that are prevalent in papillary renal cell carcinoma
    Paolo Cossu-Rocca
    Department of Pathology, Indiana University Medical Center, University Hospital, Indianapolis, IN 46202, USA
    Mod Pathol 19:488-93. 2006
    ..FISH analysis with centromeric probes for these chromosomes is potentially helpful in differentiating mucinous tubular and spindle cell carcinomas from papillary renal cell carcinomas...
  28. ncbi Molecular genetic evidence for the independent origin of multifocal papillary tumors in patients with papillary renal cell carcinomas
    Timothy D Jones
    Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA
    Clin Cancer Res 11:7226-33. 2005
    ..Molecular analysis of microsatellite and chromosome alterations and X-chromosome inactivation status in separate tumors in the same patient can be used to study the genetic relationships among the coexisting multiple tumors...
  29. ncbi Eosinophilic and classic chromophobe renal cell carcinomas have similar frequent losses of multiple chromosomes from among chromosomes 1, 2, 6, 10, and 17, and this pattern of genetic abnormality is not present in renal oncocytoma
    Matteo Brunelli
    Department of Pathology and Laboratory Medicine, Universita di Verona, Verona, Italy
    Mod Pathol 18:161-9. 2005
    ....
  30. ncbi Chromosome 14q LOH in localized clear cell renal cell carcinoma
    Kenji Mitsumori
    Department of Biochemistry, University of Otago, Dunedin, New Zealand
    J Pathol 198:110-4. 2002
    ....
  31. ncbi Few FH mutations in sporadic counterparts of tumor types observed in hereditary leiomyomatosis and renal cell cancer families
    Maija Kiuru
    Department of Medical Genetics, Biomedicum Helsinki or Haartman Institute, University of Helsinki, FIN 00014 Helsinki, Finland
    Cancer Res 62:4554-7. 2002
    ..Whereas the two former lesions were shown to originate from a germ-line mutation, the soft tissue sarcoma is to our knowledge the first example of purely somatic inactivation of FH in tumors...
  32. ncbi Prognostic importance of tumor size for localized conventional (clear cell) renal cell carcinoma: assessment of TNM T1 and T2 tumor categories and comparison with other prognostic parameters
    Brett Delahunt
    Department of Pathology, Wellington School of Medicine, University of Otago, Wellington, New Zealand
    Cancer 94:658-64. 2002
    ..This study investigates the prognostic significance of tumor size in a series of organ-confined clear cell renal cell carcinomas...